APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 2月 2022 06:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1月 2022 15:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1月 2022 06:00:00 条件 Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 12月 2021 06:00:00 条件 Nasdaq GlobeNewswire

Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

13 12月 2021 10:45:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

29 11月 2021 06:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

18 11月 2021 15:01:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

16 11月 2021 06:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

15 11月 2021 15:01:00 条件 Nasdaq GlobeNewswire

Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback

12 11月 2021 06:00:01 条件 Nasdaq GlobeNewswire